Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOF 89 EV-to-EBIT is 10.58 as of Jul. 23, 2026, which is 44% below its 10-year median of 19.04. GuruFocus rates KYKOF with a GF Score™ of 89/100 and a GF Value™ of $16.19. The stock has 1 warning sign investors should review. Among 691 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 64.98% on this metric.
Kyowa Kirin Co (OTCPK:KYKOF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kyowa Kirin Co's Enterprise Value for the quarter that ended in Dec. 2025 was $6,885 Mil.
Kyowa Kirin Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $651 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co EV-to-EBIT Related Terms
Kyowa Kirin Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's EV-to-EBIT falls into.
Kyowa Kirin Co's current Enterprise Value is $6,892 Mil.
Kyowa Kirin Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $651 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a EV-to-EBIT of 10.58 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kyowa Kirin Co and its competitors. This is 44% below median its historical median of 19.04. Over the past decade, Kyowa Kirin Co's EV-to-EBIT has ranged from 8.61 to 37.30. According to the industry distribution chart, Kyowa Kirin Co ranks #242 out of 691 companies in the Drug Manufacturers industry, placing it in the top 35%.
Is Kyowa Kirin Co's EV-to-EBIT too high?
Kyowa Kirin Co's current EV-to-EBIT of 10.58 is 44% below median its 10-year median of 19.04. Over the past 10 years, this metric has ranged from a low of 8.61 to a high of 37.30. The Drug Manufacturers industry median EV-to-EBIT is 15.70. Kyowa Kirin Co's value of 10.58 is 32.6% below this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #242 out of 691 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #242 out of 691 companies for EV-to-EBIT. This puts Kyowa Kirin Co in the upper half of its industry. The industry median EV-to-EBIT is 15.70. Kyowa Kirin Co's value of 10.58 is 32.6% below this benchmark. Historically, Kyowa Kirin Co's own EV-to-EBIT has ranged from 8.61 to 37.30 over the past decade. While the company's 10-year median is 19.04 vs. the industry median of 15.70, Kyowa Kirin Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.70, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current EV-to-EBIT of 10.58 is 32.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current EV-to-EBIT is 10.58, which is 44% below median its own 10-year median of 19.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Kyowa Kirin Co (KYKOF) has a current EV-to-EBIT of 10.58. The stock's GF Value™ is $16.19, compared to a current price of $14.43 — trading 10.9% below its estimated fair value. The current EV-to-EBIT is 10.58, which is 44% below median its 10-year median of 19.04 and 32.6% below the Drug Manufacturers industry median of 15.70. Kyowa Kirin Co's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current EV-to-EBIT is 10.58 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 10.9% below its estimated GF Value™ of $16.19.
Key valuation signals for KYKOF:
EV-to-EBIT: 10.58 (44% below median its 10-year median of 19.04)
GF Value™: $16.19 vs. price of $14.43 (10.9% below fair value)
Industry Position: 32.6% below the Drug Manufacturers median (#242 of 691)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
89GF Score
Get the complete analysis for KYKOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
